⌕
Avalo Therapeutics · AVTX · Nasdaq
Tenet 55 · Mixed
Compare
$6.76+0.15%At closeTenet 55 · Mixed
$6.76+0.01 (+0.15%)
At close: Nov 20, 2026, 4:00 PM ET· Nasdaq · USD

Avalo Therapeutics (AVTX) Stock

Avalo Therapeutics (AVTX) closed at $6.76 on Nov 20, 2026; its Tenet Score is 55 of 100 against 485 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Close
$6.76
Nov 20, 2026
Market cap
$390.9M
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
6.53 – 24.27
low → high
Tenet Score
55/100
Mixed · 485 Healthcare peers

Industry: Drugs · see every company filed here →

Avalo Therapeutics Inc scores 55/100. Mixed. Strongest on financial health and value, growth is the soft spot versus 485 Healthcare peers.

Tenet Score · vs sector

n=485
55/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
91
Quality
36
Health
92
Growth
1

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueAQualityDHealthAGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
0.9×
cap ÷ Sep 30, 2026 book value, Nov 20, 2026 close
P/S
6,625.2×
price to sales
ROE
−34%
TTM through Sep 30, 2026
Operating margin
−123601.7%
fiscal 2025, before interest and tax
Net margin
—
Not reported in the company's filings for this period.
Current ratio
16.63
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Avalo Therapeutics Inc

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a ful…

Composite computed Nov 21, 2026 · peer basis: Healthcare (n=485) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 47 US ETFs · top wrappers by weightSee all ETFs holding AVTX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Avalo Therapeutics in?

Avalo Therapeutics is in the Healthcare sector and the Drugs industry.

What is Avalo Therapeutics' Tenet Score?

Avalo Therapeutics' Tenet Score is 55 out of 100, ranked against 485 Healthcare peers as of Nov 21, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.